Company intelligence / Profile preview

Valens Funds

Bethesda, Maryland, United Statesacelyrin.com ↗

Ownership: Private
Development stage: Other

Overview

ValenzaBio is a clinical-stage biotechnology company focused on developing monoclonal antibodies for the treatment of autoimmune and inflammatory diseases. The company's lead program, VB-421, is a potent IGF-1R antagonist designed to treat Thyroid Eye Disease (TED) with a potentially improved safety and efficacy profile compared to existing therapies. Another key asset, VB-119, targets c-KIT for the treatment of Chronic Spontaneous Urticaria (CSU) and other mast cell-mediated disorders. ValenzaBio was acquired by Acelyrin in early 2023, significantly expanding Acelyrin's immunology pipeline with multiple clinical and pre-clinical programs.

Therapeutic areas: EndocrinologyDermatology
Modalities: Monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Valens Funds.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Valens Funds.

Explore the full profile